The Journal of antimicrobial chemotherapy · 2026
Differences in prescription for impetigo and cellulitis across years in three European countries.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bettuzzi Thomas, Strady Christophe, Diamantis Sylvain, Matta Matta
Аннотация
BACKGROUND: Cellulitis and impetigo account for many outpatients' visits and antibiotic prescriptions. They are mainly caused respectively by Streptococcus spp. and Staphylococcus aureus. French guidelines recommend amoxicillin as a first-line antibiotic for cellulitis and pristinamycin for severe impetigo, whereas the UK guidelines recommend flucloxacillin for both infections and no Belgian guidelines are published.
OBJECTIVES: To investigate the prescription patterns of cellulitis and impetigo in general practice and to assess the potential impact of the implementation of national guidelines.
METHODS: We used a prescription software database (Cegedim) from 2013 to 2023 in France, the UK and Belgium. The annual rate of antibiotic prescription associated with cellulitis and impetigo was assessed. A segmented linear regression was performed to assess the impact of the implementation of the guidelines in 2019.
RESULTS: The use of amoxicillin for the diagnosis of cellulitis increased from 18.2% to 36.2% in France. Flucloxacillin use increased from 41.1% to 51.6% in the UK. In Belgium, no change in antibiotic use was observed with amoxicillin-clavulanate being the most commonly prescribed antibiotic.In France, the use of pristinamycin and amoxicillin-clavulanate for the diagnosis of impetigo increased from 13.8% and 22.2% to 21.1% and 33.1%, respectively. In Belgium and the UK, flucloxacillin was the most commonly prescribed antibiotic, with prescription rates increasing from 55.7% to 62.6% and from 71.8% to 82.6%, respectively.Publication of guidelines did not affect antibiotic prescribing patterns.
CONCLUSION: Prescribing patterns are very heterogeneous across European countries and publication of guidelines did not affect prescribing habits.
OBJECTIVES: To investigate the prescription patterns of cellulitis and impetigo in general practice and to assess the potential impact of the implementation of national guidelines.
METHODS: We used a prescription software database (Cegedim) from 2013 to 2023 in France, the UK and Belgium. The annual rate of antibiotic prescription associated with cellulitis and impetigo was assessed. A segmented linear regression was performed to assess the impact of the implementation of the guidelines in 2019.
RESULTS: The use of amoxicillin for the diagnosis of cellulitis increased from 18.2% to 36.2% in France. Flucloxacillin use increased from 41.1% to 51.6% in the UK. In Belgium, no change in antibiotic use was observed with amoxicillin-clavulanate being the most commonly prescribed antibiotic.In France, the use of pristinamycin and amoxicillin-clavulanate for the diagnosis of impetigo increased from 13.8% and 22.2% to 21.1% and 33.1%, respectively. In Belgium and the UK, flucloxacillin was the most commonly prescribed antibiotic, with prescription rates increasing from 55.7% to 62.6% and from 71.8% to 82.6%, respectively.Publication of guidelines did not affect antibiotic prescribing patterns.
CONCLUSION: Prescribing patterns are very heterogeneous across European countries and publication of guidelines did not affect prescribing habits.